I. PURPOSE

To define and describe the accepted indications for Cyramza™ (ramucirumab) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century is responsible for processing all medication requests from network ordering providers. Medications not authorized by New Century may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

1. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

   a. When health plan Medicaid coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR
   
   b. When health plan Exchange coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR
   
   c. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways when applicable, otherwise shall follow NCH drug policies AND
   
   d. Continuation requests of previously approved non-preferred medication are not subject to this provision AND
   
   e. When available, generic drug alternatives are preferred over Brand name drugs.

2. Gastric and Gastroesophageal Junction Cancers

   a. NOTE: Cyramza™ (ramucirumab) is a non-preferred agent per NCH Policy & NCH Pathway. The preferred alternatives per NCH Policies & NCH Pathway, for subsequent therapy of advanced/metastatic gastric or gastroesophageal junction adenocarcinoma are single agents including paclitaxel, docetaxel, or irinotecan.
   
   b. Please refer to the NCH Pathway document for recommended regimens for the above cancer types
3. Non-Small Cell Lung Cancer (NSCLC)/Colorectal Carcinoma/Hepatocellular Carcinoma
   a. Cyramza (ramucirumab) is a non-preferred drug for the treatment of all the above cancer
      types. Please refer to the NCH Pathway document for recommended/preferred
      regimens/agents for the above cancer types.

III. EXCLUSION CRITERIA
   1. Disease progression while taking Cyramza (ramucirumab).
   2. Dosing exceeds single dose limit of Cyramza (ramucirumab) 10 mg/kg.
   3. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. MEDICATION MANAGEMENT
   Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY
   1. Review – Utilization Management Department
   2. Final Approval – Utilization Management Committee

VI. ATTACHMENTS
   None

VII. REFERENCES